FDA Partners
FDA Partners
  • HOME
  • SERVICES
    • FOR COMPANIES
    • FOR INVESTORS
  • ABOUT
  • OUR TEAM
  • More
    • HOME
    • SERVICES
      • FOR COMPANIES
      • FOR INVESTORS
    • ABOUT
    • OUR TEAM
CONTACT US
  • HOME
  • SERVICES
    • FOR COMPANIES
    • FOR INVESTORS
  • ABOUT
  • OUR TEAM
CONTACT US

SERVICES FOR INVESTORS

ACCELERATING RETURNS. NAVIGATING COMPLEX LANDSCAPES.


Financial metrics only tell half the story. FDA regulatory risk is one of the most consequential variables in shaping asset value.


We bridge the gap between financial potential and FDA regulatory reality. We function as an extension of your investment team, validating your thesis before the deal closes and accelerating your portfolio's path to exit.

THE CORE VALUE: TIME IS REVENUE

In the biotech sector, delays are measured in millions. For a blockbuster asset, every single day on the U.S. market can generate at least ~$1M in profit. Taking an extra 60 days to get FDA approval could cost a portfolio company ~$60M in lost revenue [1].

[1] Day of Delay White Paper Final

The Speed Advantage

The Speed Advantage

The Speed Advantage

We specialize in identifying expedited strategies to maximize asset valuation and shorten timelines.

Getting "Unstuck"

The Speed Advantage

The Speed Advantage

We intervene when assets stall. We deploy senior expertise to resolve clinical holds and negotiate directly with FDA review divisions to get the product moving again. 

THE EXPERTISE: WE WROTE THE TRAINING MANUAL

Navigating the FDA requires more than reading the rules; it requires understanding the people who wrote them.

Former FDA & Industry Leaders

Former FDA & Industry Leaders

Former FDA & Industry Leaders

Our team is comprised of former FDA senior officials, industry veterans, and academic stakeholders with 250+ years of combined insight. 

Teaching the Regulator

Former FDA & Industry Leaders

Former FDA & Industry Leaders

We created internal training materials for FDA Medical Officers and Pre-Market Reviewers that are still used to this day.

Proven Outcomes

Former FDA & Industry Leaders

Proven Outcomes

We helped over a dozen companies secure marketing authorizations, including the first-ever FDA Breakthrough Device Designation (BDD) for treating Alzheimer’s disease.

SERVICE OFFERING FOR THE INVESTOR

The Strategic Advantage: Intelligence & Policy

Success belongs to those astute enough to keep pace with rapid advancements in FDA regulatory policy. We help your portfolio companies leverage new and novel policies to their advantage, utilizing these shifts to expedite approvals and reduce clinical burdens and associated costs.

Forensic Regulatory Diligence (Pre-Deal)

We uncover what the pitch deck hides. Our deep-dive audits of clinical datasets and correspondence substantiate scientific claims to de-risk your entry.

Strategic Intervention (Post-Deal)

  • Feasibility & Modeling: We validate the use of novel technologies like in-silico modeling, AI/ML-based Tools, and Real World Data/Evidence (RWD/RWE) to ensure the proposed clinical path is viable and cost-efficient.
  • Lifecycle Management: We provide full-service support for clinical study design and oversight to ensure your portfolio companies generate submission-ready data.

LET'S DEFINE THE PROBLEM

Your portfolio’s next FDA hurdle shouldn’t be a surprise. Let’s meet to discuss the specific regulatory or clinical bottlenecks currently threatening your assets and define a roadmap to clear them.

CONTACT US
  • HOME
  • FOR COMPANIES
  • FOR INVESTORS
  • ABOUT
  • OUR TEAM
  • CONTACT US

Copyright © 2026 FDA Partners - All Rights Reserved.

FDA Partners - contact@fda-partners.com

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept